Radiopharm Theranostics Ltd (ASX:RAD) has welcomed the release of Imperial College London's F-18 Pivalate (RAD 101) Phase 2a data in patients with brain metastases, showing significant tumour uptake that was consistent and independent from the tumour origin.
A full presentation of the results will take place at the 34th EORTC/AACR/NCI symposium in Barcelona (26-28 October 2022).
The study was funded by the Medical Research Council and will also be published in a peer-reviewed journal in due course.
Promising theranostic approach
Radiopharm CEO and managing director Riccardo Canevari said: “We are very pleased to see a new molecule and an innovative mode of action showing significant results in brain cancer metastases.
“The team at Imperial College London, led by Professor Eric Aboagye, did a tremendous job.
“F-18 Pivalate and its potential therapeutic variations, currently under development, represent a promising theranostic approach to target brain metastases and potentially other brain tumours.
“These positive and encouraging results will inform F-18 Pivalate accelerated future development and we are looking forward to starting conversations with medical experts and regulatory agencies.”
Superior imaging performance
Professor Aboagye, from Imperial College London and the lead inventor of F-18 Pivalate, added: “This technology, when compared to the current clinical standard in PET imaging, has showed superior imaging performance in several cancers.
“We’re very pleased to see this interim data further confirms its potential.”
Radiopharm had acquired an exclusive worldwide licence for the Pivalate platform technology from Cancer Research Technology Limited and Imperial College London, and has a Sponsored Research Agreement on new analogues with Professor Aboagye.
The company will remain in voluntary suspension until Thursday, 20 October 2022, pending an announcement regarding a capital raise.